Kala Bio (KALA) Cash from Operations (2016 - 2026)
Kala Bio (KALA) posted Cash from Operations of 2895000.0 for Q1 2026, up 36.46% sequentially from 4556000.0 in Q4 2025, and up 67.19% YoY from 1731544.77 in Q1 2025.
Kala Bio (KALA) Cash from Operations (2016 - 2026) Analysis & Trends
Kala Bio has reported Cash from Operations for 11 years, with the latest figure at 2895000.0 in Q1 2026.
- Quarterly Cash from Operations rose 67.19% year-over-year to 2895000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34886000.0 (down 27.5% YoY) and the FY2025 annual result came in at 31991000.0, down 8.88% from the prior year.
- Cash from Operations grew to 2895000.0 in Q1 2026 per KALA's latest filing, from 4556000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 2895000.0 in Q1 2026 and troughed at 25419000.0 in Q2 2022.
- A 5-year average of 10583941.18 and a median of 9215000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2023 and 2025: Cash from Operations soared 81.16% in 2023, then tumbled 130.2% in 2025.
- Over 5 years, Cash from Operations stood at 13735000.0 in 2022, then surged by 43.97% to 7696000.0 in 2023, then surged by 40.25% to 4598000.0 in 2024, then climbed by 0.91% to 4556000.0 in 2025, then soared by 36.46% to 2895000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 2895000.0, 4556000.0, and 10877000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 326.72 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -88.83 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 728.46 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 360.27 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | -2.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.90 Mn |
| Mar 31, 2026 | -2.90 Mn |
| Dec 31, 2025 | -4.56 Mn |
| Dec 31, 2025 | -4.56 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Sep 30, 2025 | -10.88 Mn |
| Jun 30, 2025 | -16.56 Mn |
| Jun 30, 2025 | -16.56 Mn |
| Mar 31, 2025 | -8.82 Mn |
| Mar 31, 2025 | -8.82 Mn |
| Dec 31, 2024 | -4.60 Mn |
| Dec 31, 2024 | -4.60 Mn |
| Sep 30, 2024 | -4.73 Mn |
| Sep 30, 2024 | -4.73 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Jun 30, 2024 | -9.22 Mn |
| Mar 31, 2024 | -10.84 Mn |
| Mar 31, 2024 | -10.84 Mn |
| Dec 31, 2023 | -7.70 Mn |
| Dec 31, 2023 | -7.70 Mn |